Photo of Ana Corregidor MD

Ana Corregidor MD

Encore Borland Groover Clinical Research
Clinical Research Location 4800 Belfort Road Jacksonville FL 32256 Contact Research: (904) 680-0871

Biography

Dr. Corregidor joins us after completing her transplant/hepatology fellowship at the MAYO Clinic in Jacksonville. In addition to her special training in liver diseases, Ana completed a fellowship in gastroenterology at the University of Florida. She has a special interest in pre and post liver transplant evaluation and management. Dr. Corregidor is the medical director of Borland Groover’s Liver Center, and is active in several clinical trials investigating new drugs in the treatment of Hepatitis C and B and other liver diseases. In addition, Dr. Corregidor performs colonoscopy and upper endoscopy.

Participate in Current Trials 


NASH
Contact Research

Postgraduate Education

Postgraduate Education
2001 – 2002
Fellowship, Hepatology and Liver Transplantation
Mayo Clinic Jacksonville, Jacksonville, FL
2001 – 1998
Fellowship, Gastroenterology
University of Florida, Shands, Jacksonville, FL
1998 – 1995
Internship and Residency: Internal Medicine
St. Lukes Hospital, University of Columbia, MO St. Louis, MO

RESEARCH TRAINING:

1/9/2018 CITI Good Clinical Practice

9/22/2017 Pfizer SIRIUS for Safety Reporting Training v1.0

9/21/2017 Pfizer C1171002 Protocol Specific Training v1.0

9/14/2017 Fibroscan 530 Training Certificate

4/19/2016 TransCelerate ICH GCP

5/8/2015 Rave EDC Essentials for Clinical Research Coordinators

4/25/2014 TransCelerate ICH GCP

4/24/2012 CITI Good Clinical Practice

RESEARCH EXPERIENCE:

Principal Investigator:

2020-Present Enanta EDP305-102, NASH

2019 Pfizer C1061011, NAFLD

2018-2019 Enanta EDP305-301, NASH

2017-2019 Pfizer C1171002, NASH

2016 Novartis CLJN452A2202, Liver Disease

2016 Eisai E5501-G000-30, Liver Disease

2015 AbbVie M13-590, Hepatitis C

2015 AbbVie M15-410, Hepatitis C

2015 Janssen TMC435HPC2013, Hepatitis C

2012 Janssen TMC435HPC2002, Hepatitis C

2011 Janssen TMC435HPC3007A, Hepatitis C

2011 Janssen TMC435-TiDP16-C216A, Hepatitis C

2011 Janssen TMC435HPC3007A, Hepatitis C

2011 Janssen TMC435-TiDP16-C216A, Hepatitis C

Sub-Investigator:

2020-Present Neurogastrx NG101-201, Gastroparesis

2020-Present Lucid EG-CL-102, Adenocarcinoma

2020-Present Lucid EG-CL-101, Barrett’s Esophagus

2020-Present Allakos AK002-014, Eosinophilic Esophagitis

2020-Present Allakos AK002-016, Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis

2020-Present Allakos AK002-019, Eosinophilic Gastrointestinal Diseases

2020-Present Phathom HP-301, H. Pylori

2020-Present Phathom EE-301, Erosive Esophagitis

2019-Present AbbVie M14-234, Ulcerative Colitis

2019-Present AbbVie M14-533, Ulcerative Colitis

2019-Present AbbVie M14-675, Ulcerative Colitis

2019-Present AbbVie M14-430, Crohn’s Disease

2019-Present AbbVie M14-431, Crohn’s Disease

2019-Present AbbVie M14-433, Crohn’s Disease

2019-Present Gilead GS-US-365-4237 FALCON, Ulcerative Colitis

2019-Present Braintree BLI4900-302, Colon Prep

2019-Present Adare SP-1011-003, Eosinophilic Esophagitis

2019-Present Finch CDI-001, C-difficile

2017 Celgene GED-0301-CD-002, Crohn’s Disease

2016 Boehringer Ingelheim 1297.4, Crohn’s Disease

2016 SERES 101, Ulcerative Colitis

2015 Gilead GS-US-337-1431, Hepatitis C

2015 Gilead GS-US-342-1446, Hepatitis C

2015 Gilead GS-US-367-1168, Hepatitis C

2015 Gilead GS-US-367-1169, Hepatitis C

2014 Synageva LAL-CSS01, Lysosomal Acid Lipase Deficiency

2014 AbbVie M14-222 “TOPAZ II”, Hepatitis C

2014 AbbVie M14-490 “TURQUOISE III”, Hepatitis C and Cirrhosis

2014 Gilead GS-US-342-1553, Hepatitis C

2014 Gilead GS-US-342-1137, Chronic Hepatitis C and Child-Pugh Class B Cirrhosis

2014 Gilead GS-US-342-1138, Chronic Hepatitis C

2014 Gilead GS-US-342-1139, Chronic Genotype 2 Hepatitis C

2014 Gilead GS-US-342-1140, Chronic Genotype 3 Hepatitis C

2014 Janssen TMC435HPC3017, Genotype 1 Chronic Hepatitis C

2013 BMS AI443-102, Genotype 1 Chronic Hepatitis C

2013 BMS AI443-113, Genotype 1 Chronic Hepatitis C

2013 AbbVie M13-102, Chronic Hepatitis C

2013 AbbVie M14-004 “TURQUOISE I”, Genotype 1 Chronic Hepatitis C

2013 Gilead GS-US-337-0108A, Chronic Genotype 1 Hepatitis C

2013 Gilead GS-US-342-0102, Chronic Hepatitis C

2013 Janssen TMC435-TIDP16, Hepatitis C

2013 Gilead GS-US-342-0109, Chronic Hepatitis C

2012 BMS AI444058, Hepatitis

2012 AbbVie M13-098, “SAPPHIRE II”, Genotype 1 Chronic Hepatitis C

2012 Braintree BLI800-440, Bowel Cleansing Treatments

2012 Gilead GS-US248-0122, Chronic Hepatitis C

2012 Janssen CNTO1275CRD3003 “IMUNITI”, Crohn’s Disease

2012 Janssen CNTO1275CRD3002 “UNITI 2”, Crohn’s Disease

2012 Gilead GS-US-334-0110, Chronic Genotype 1, 4, 5, or 6 Hepatitis C

2012 Gilead GS-US-337-0109, Chronic Genotype Hepatitis C

2012 Gilead GS-US-334-0110, Chronic Genotype 1, 4, 5, or 6 Hepatitis C

2012 Vertex VX11-950-114, Genotype 1 Chronic Hepatitis C and IL28B CC Genotype

2012 Gilead GS-US-337-0108, Chronic Genotype 1 Hepatitis C

2011 Tibotec TMC435-TiDP16-C213, Genotype 1 Hepatitis C

2011 Gilead GS-US-248-0120, Chronic Genotype 1 Hepatitis C

2011 Janssen TMC435-HPC-3002, Hepatitis C

2011 Gilead GS-US-334-0107, Chronic Genotype 2 or 3 Hepatitis C

2011 Janssen CNTO1275CRD3001 “UNITI 1”, Crohn’s Disease

2011 Gilead GS-US-334-0108, Chronic Genotype 2 or 3 Hepatitis C

2011 AbbVie M11-652, Genotype 1 Chronic Hepatitis C

2011 Vertex VX11-950-115, Genotype 1 Hepatitis C and HIV Type 1

2011 Vertex VX08-950-112 “EXTEND”, Hepatitis C

2011 Gilead GS-US-256-0148, Chronic Genotype 1 Hepatitis C

2010 Millennium C13007, Crohn’s Disease

2010 DLS ID20100308, Collection of Clinical Sample Sets for the Detection of HBV DNA and HCV RNA in Serum and Plasma from Subjects with Clinically Defined Disease

2007 Vertex VX06-950-107, Hepatitis C

2007 Valeant RNA003142-204, Chronic Genotype 1 Hepatitis C

2007 BMS IM101084, Crohn’s Disease

2007 BMS IM101108, Crohn’s Disease

2007 Shire SPD476-404, Ulcerative Colitis

2007 Valeant RNA003142-204, Chronic Hepatitis C Virus Genotype 1 Infection

2004 Roche NV17317, Chronic Hepatitis C

1.Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756–1765.

2.Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lawitz E1, Sulkowski MS2, Ghalib R3, Rodriguez-Torres M4, Younossi ZM5, Corregidor A6, DeJesus E7, Pearlman B8, Rabinovitz M9, Gitlin N10, Lim JK11, Pockros PJ12, Scott JD13, Fevery B14, Lambrecht T15, Ouwerkerk-Mahadevan S14, Callewaert K14, Symonds WT16, Picchio G17, Lindsay KL17, Beumont M14, Jacobson IM18

3.45 year old woman with lower abdominal pain and constipation

4.Oral presentation at ACG National Fellows Forum, San Diego, California, 1999